Explore more publications!
California Health Watch
Got News to Share?

California Health Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on California Health Watch.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on September 29, 2025

Tower 25 Nominated for Best Digital Marketing Firm in Southern California by the Santa Monica Daily Press
September 29, 2025

Tower 25 Nominated for Best Digital Marketing Firm in Southern California by the Santa Monica Daily Press

Indeterminate EIN Presswire
C-Suite Webinar on Data Standardization Blueprint to Unlock Health IT ROI and Drive Savings for Hospitals — this Wed.
September 29, 2025

C-Suite Webinar on Data Standardization Blueprint to Unlock Health IT ROI and Drive Savings for Hospitals — this Wed.

Indeterminate EIN Presswire
Dr. Rebecca Johnson Osei Once Again Takes Home the ThreeBestRated® Award for 2025
September 29, 2025

Dr. Rebecca Johnson Osei Once Again Takes Home the ThreeBestRated® Award for 2025

Indeterminate EIN Presswire
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
September 29, 2025

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Indeterminate GlobeNewswire
NANOBIOTIX annonce de nouveaux résultats de Phase 1 qui continuent de confirmer le potentiel de JNJ-1900 (NBTXR3), avec un anti-PD-1, en tant que potentielle nouvelle option thérapeutique de première ou deuxième ligne ou plus dans le CETEC R/M naïf ou …
September 29, 2025

NANOBIOTIX annonce de nouveaux résultats de Phase 1 qui continuent de confirmer le potentiel de JNJ-1900 (NBTXR3), avec un anti-PD-1, en tant que potentielle nouvelle option thérapeutique de première ou deuxième ligne ou plus dans le CETEC R/M naïf ou …

Indeterminate GlobeNewswire
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
September 29, 2025

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

Indeterminate GlobeNewswire
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements
September 29, 2025

Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements

Indeterminate GlobeNewswire
INVO Fertility to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
September 29, 2025

INVO Fertility to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Indeterminate GlobeNewswire
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
September 29, 2025

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

Indeterminate GlobeNewswire
Sybill and Enable Partner to Bring AI‑Powered CRM Hygiene to Zoho Customers
September 29, 2025

Sybill and Enable Partner to Bring AI‑Powered CRM Hygiene to Zoho Customers

Indeterminate EIN Presswire
Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
September 29, 2025

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

Indeterminate GlobeNewswire
Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates
September 29, 2025

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Indeterminate GlobeNewswire
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
September 29, 2025

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Indeterminate GlobeNewswire
Precision Optics Reports Fourth Quarter and Fiscal Year 2025 Financial Results
September 29, 2025

Precision Optics Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Indeterminate GlobeNewswire
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
September 29, 2025

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Indeterminate GlobeNewswire
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
September 29, 2025

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Indeterminate GlobeNewswire
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
September 29, 2025

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Indeterminate GlobeNewswire
Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2025

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
September 29, 2025

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Indeterminate GlobeNewswire
ImmuCell Announces Selection of its Next President and CEO
September 29, 2025

ImmuCell Announces Selection of its Next President and CEO

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions